TY - JOUR
T1 - Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
T2 - An observational study
AU - Hochmair, Maximilian J.
AU - Morabito, Alessandro
AU - Hao, Desiree
AU - Yang, Cheng Ta
AU - Soo, Ross A.
AU - Yang, James C.H.
AU - Gucalp, Rasim
AU - Halmos, Balazs
AU - Wang, Lara
AU - Golembesky, Amanda
AU - Märten, Angela
AU - Cufer, Tanja
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT0337077.
AB - Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT0337077.
KW - afatinib
KW - NSCLC
KW - osimertinib
KW - sequential
KW - T790M
UR - http://www.scopus.com/inward/record.url?scp=85056628463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056628463&partnerID=8YFLogxK
U2 - 10.2217/fon-2018-0711
DO - 10.2217/fon-2018-0711
M3 - Article
C2 - 30336693
AN - SCOPUS:85056628463
VL - 14
SP - 2861
EP - 2874
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 27
ER -